Priority-driven Collaborative Cancer Research Scheme 2011

Cancer Australia; beyondblue, the national depression and anxiety initiative; Cancer Council Australia; Cancer Council New South Wales; Cure Cancer Australia Foundation; Leukaemia Foundation; National Breast Cancer Foundation; and the Prostate Cancer Foundation of Australia, are pleased to announce applicants who have been recommended for funding in the 2011 Round of the Priority-driven Collaborative Cancer Research Scheme.

Anderson, R

Peter MacCallum Cancer Centre

Targeting dormancy in metastatic breast cancer

Co-funded by National Breast Cancer Foundation and Cancer Australia

Buchanan, G

University of Adelaide

Androgen receptor action in the prostate cancer microenvironment
Co-funded by Prostate Cancer Foundation of Australia and Cancer Australia

Butow, P

University of Sydney

Evaluation of a psychological and educational intervention for fear of cancer recurrence; a cluster randomised controlled trial

Co-funded by beyondblue, National Breast Cancer Foundation and Cancer Australia

Campbell, H

Children's Medical Research Institute

Mechanism of Δ 133p53 isoform oncogenicity

Co-funded by Cure Cancer Australia Foundation and Cancer Australia

Chen, V

University of New South Wales

Thromboembolism in cancer

Co-funded by Cure Cancer Australia Foundation and Cancer Australia

Day, B

Queensland Institute of Medical Research

Salinomycin a potential glioma stem cell targeting therapy

Co-funded by Cure Cancer Australia Foundation and Cancer Australia

Ge, Y

University of Sydney

Treating deforming tumours with real-time adaptive radiotherapy Funded by Cure Cancer Australia Foundation

Holloway, L

Liverpool Hospital

Quantifying the impact of imaging choice for breast cancer radiotherapy Co-funded by National Breast Cancer Foundation and Cancer Australia

Kiely, B

University of Sydney

Evaluation of a web-based tool for estimating and explaining prognosis in advanced cancer Co-funded by beyondblue and Cancer Australia

Lees, J

Kids Research Institute

Inhibition of glioblastoma invasion by novel Dynamin ring stabilisers Co-funded by Cure Cancer Australia Foundation and Cancer Australia

Lehman, M

Princess Alexandra Hospital

A randomised phase III trial of High Dose Palliative Radiotherapy (HDPRT) versus Concurrent Chemotherapy and HDPRT (C-HDPRT) in patients with good performance status, locally advanced/small volume metastatic Non-small Cell Lung Cancer not suitable for radical chemo-radiotherapy

Funded by Cancer Australia

McArthur, G

Peter MacCallum Cancer Centre

Determining predictors of sensitivity to Chk inhibitors in metastatic melanoma Funded by Cancer Australia

McDonald, K

University of New South Wales

Mechanisms underpinning how brain cancer cells respond to drugs Funded by Cancer Council New South Wales

McNees, K

Children's Medical Research Institute

The role of single stranded DNA binding proteins in the Alternative Lengthening of Telomeres mechanism

Co-funded by Cure Cancer Australia Foundation and Cancer Australia

Mileshkin, L

Peter MacCallum Cancer Centre

PORTEC-3 - the role of adjuvant chemotherapy in high-risk endometrial cancer Funded by Cancer Australia – gynaecological cancers program

Mitchell, G

Peter MacCallum Cancer Centre

Defining the hereditary contribution to ovarian cancer: The role of mismatch repair genes Funded by Cancer Australia

Neilson, P

University of Adelaide

Reactivating the p53 pathway as a novel therapeutic approach to cancer treatment Co-funded by Cure Cancer Australia Foundation and Cancer Australia

Newton, R

Edith Cowan University

Can exercise ameliorate treatment toxicity during the initial phase of testosterone suppression in prostate cancer patients? Is this more effective than delayed rehabilitation and what is the time course and persistence of benefits?

Co-funded by beyondblue, Prostate Cancer Foundation of Australia and Cancer Australia

Nguyen, A

Garvan Institute of Cancer Research

The role of p53-regulated microRNAs in epithelial to mesenchymal transition, and their potential as therapeutic targets against metastatic breast cancer

Co-funded by Cure Cancer Australia Foundation and Cancer Australia

Nowak, A

University of Western Australia

Phase III trial of Concurrent and Adjuvant Temozolomide chemotherapy in non-1p/19q nondeleted anaplastic glioma. The CATNON Intergroup Trial Co-funded by Cancer Council Australia and Cancer Australia

Reid, G

Asbestos Diseases Research Institute

The use of RNAi to identify new therapeutic targets for malignant mesothelioma Funded by Cancer Australia

Scarlett, C

Garvan Institute of Cancer Research

The therapeutic potential of targeting S100A2 calcium-binding protein in pancreatic cancer Co-funded by Cure Cancer Australia Foundation and Cancer Australia

Severi, G

Cancer Council Victoria

Risk and prognostic factors for glioma in Australia

Co-funded by Cancer Council Australia and Cancer Council New South Wales

Sieber, O

Ludwig Institute for Cancer Research

Discovery of colorectal cancer subtype associated tumour suppressor genes using nextgeneration sequencing and high throughput functional genomics Funded by Cancer Australia

Singh, R

University of Adelaide

A novel method to detect and characterise dysplasia and early cancer in Barrett's oesophagus

Co-funded by Cure Cancer Australia Foundation and Cancer Australia

Suryadinata, R

St Vincent's Institute of Medical Research

Cumulative cyclin-dependent kinase-mediated phosphorylation of pRb and RBP1 tumour suppressors controls cell cycle progression
Funded by Cure Cancer Australia Foundation

Vardy, J

University of Sydney

Ginkgo biloba preserves cognitive function in women treated with adjuvant chemotherapy for early breast cancer: a double-blind, placebo-controlled, randomised phase III trial Co-funded by beyondblue, National Breast Cancer Foundation and Cancer Australia

Waithman, J

Ludwig Institute for Cancer Research

The initiation of the cellular immune response to cutaneous melanoma Co-funded by Cure Cancer Australia Foundation and Cancer Australia

Wakefield, C

University of New South Wales

'ReCaPTure LiFe': A phase II randomised trial of a psychological intervention to support adolescent and young adult cancer survivors

Co-funded by beyondblue and Cancer Australia

Zannettino, A

SA Pathology

Is elevated N-cadherin expression a poor prognostic indicator in multiple myeloma patients? Co-funded by Leukaemia Foundation and Cancer Australia